Navigation Links
Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in,Preclinical Studies

LUCCA, ITALY, ­ May 14, 2007-Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced results of a preclinical study with ACE-031 that demonstrated the ability of the compound to increase muscle mass and strength in normal mice and in murine models of muscular dystrophy. ACE-031 inhibits negative regulators of muscle to increase muscle mass and strength as a potential treatment for neuromuscular diseases and cancer-related muscle loss. The data was presented on Sunday, May 13 at the Gordon Research Conference on Myogenesis in Lucca, Italy. ³

Acceleron is encouraged by the significant outcomes and positive data generated by ACE-031 spanning numerous preclinical models of muscle loss², said Jas Seehra, Ph.D., Chief Scientific Officer of Acceleron. ³ACE-031 and related Acceleron compounds consistently demonstrate substantial increases in skeletal muscle mass and strength.² ACE-031, a protein therapeutic based on the activin receptor type IIB (ActRIIB), is the first of several compounds Acceleron is developing for the treatment of diseases involving the loss of muscle mass, strength and function. ActRIIB binds to myostatin (GDF-8) and other negative regulators of muscle mass and strength. Over-expression of myostatin has been shown to cause a loss in muscle mass and strength, and inhibition of myostatin results in the selective increase in skeletal muscle mass and strength. In preclinical models, ACE-031 increased skeletal muscle mass and strength in disease models of amyotrophic lateral sclerosis (ALS), muscular dystrophy, glucocorticoid-induced muscle loss and age-related muscle loss (sarcopenia).

ACE-031 offers the potential for an entirely new type of therapy for the treatment of various muscle wasting conditions. ³The clinical potential of ACE-031 to selectively increase skeletal muscle will offer a growing number of patients an excellent opportunity to benefit from a promising therapy for the otherwise untreatable muscle loss associated with their disease,² said Matthew L. Sherman, M.D., Chief Medical Officer of Acceleron. ³

Based on the comprehensive preclinical program currently underway, Acceleron is working toward advancing ACE-031 into Phase 1 clinical trials later this year.² Study Findings The presentation, entitled ³Treatment with a Soluble Activin Receptor IIB Causes Increased Muscle Mass and Strength in mdx Mice² discussed data from preclinical studies in normal mice and in a mouse model of muscular dystrophy. These studies show a substantial increase in muscle mass and a dose-dependent increase in lean body mass in treated animals. These effects are significant in just two weeks following start of therapy and increase further as treatment continues. In the mdx murine model of muscular dystrophy, treated animals showed increases in muscle mass which translated into significantly increased muscle strength.

About Muscle Loss
Loss of muscle mass and strength is a serious clinical consequence of several types of diseases and conditions: (1) neuromuscular diseases, such as ALS and muscular dystrophy, in which patients suffer from the loss of muscle strength and function which ultimately leads to respiratory failure and death (2) cancer-cachexia, in which patients can lose muscle mass and body weight as a result of both their cancer treatments (hormone deprivation therapy causes loss of muscle) and the cancer itself (3) other cachexias, in which the muscle loss is associated with chronic diseases such as congestive heart failure, chronic obstructive pulmonary disease, and chronic kidney disease and, (4) age-related muscle loss, known as sarcopenia, in which generalized muscle loss and frailty leads to frequent falls and morbidity and mortality from broken bones. A drug candidate that would increase muscle mass and strength is expected to produce a major clinical benefit across this broad range of serious medical conditions in which there are currently no safe and effective therapies that selectively increase skeletal muscle mass and strength.

About Acceleron Pharma
Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron¹s scientific approach takes advantage of its unique insight on the regenerative powers of two protein families: the Growth and Differentiation Factor (GDF) and Bone Morphogenetic Protein (BMP) families. The company¹s lead program is an anabolic bone agent being developed to reverse bone loss in diseases such as osteoporosis and cancer. Additionally, the company is advancing several preclinical programs that increase muscle mass, control angiogenesis and inhibit fat accumulation. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company¹s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock.

Contact: Steven Ertel, Vice President, Business Development, Acceleron Pharma, tel: 617-520-1334 and Paul Kidwell (Media) Suda Communications, tel: 617-296-3854 Paul Kidwell 617.296.3854: Office 617.680.1088: Mobile


Related medicine technology :

1. Acceleron Pharmas ACE-031 Increases Muscle Mass and Strength in Preclinical Studies
2. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
3. Rapid HIV Testing Increases Possibility of Treatment
4. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
5. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells
6. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
7. Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)
8. New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits
9. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
10. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
11. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
Post Your Comments:
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):